0758 GMT - Haleon's full-year results are solid, with a 2025 outlook in line with consensus forecasts, RBC Capital Markets analysts say in a note. The British consumer-health company's 2024 results came in slightly ahead of consensus, despite analysts' and investors' concerns around a depressed North American flu season in 4Q, they say. For 2025, the company has guided for organic revenue growth to be in the range of 4% to 6% and organic operating profit growth ahead of sales growth. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 27, 2025 02:58 ET (07:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.